Prosecution Insights
Last updated: November 12, 2026
Application No. 17/087,385

METHODS AND SYSTEMS FOR QUANTIFYING SEQUENCE ALIGNMENT

Non-Final OA §112§DOUBLEPATENT
Filed
Nov 02, 2020
Priority
Oct 18, 2013 — provisional 61/892,666 +1 more
Examiner
WHALEY, PABLO S
Art Unit
3619
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Seven Bridges Genomics Inc.
OA Round
4 (Non-Final)
25%
Grant Probability
At Risk
4-5
OA Rounds
46%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
136 granted / 544 resolved
-27.0% vs TC avg
Strong +21% interview lift
Without
With
+21.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
595
Total Applications
across all art units

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/09/2026 has been entered. Status of Claims Claims 21, 24-26, 28, 31-35, 38-42 are under examination. Claims 1-20, 22-23, 27, 29-30, 36-37 are cancelled. Priority This application claims priority under 35 U.S.C. § 120 and is a continuation of U.S. Application No. 14/517,419, filed October 17, 2014, which claims priority under 35 U.S.C. § 119(e) to U.S. Patent Application No. 61/892,666, filed October 18, 2013. Accordingly, the effective filing date of this application is October 18, 2013. Withdrawn Rejections The rejection of claims 21, 24-28, 31-35, 38-42 under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more is withdrawn in view of applicant’s amendments and arguments. In particular, the amended claims further limit the DAG data structure to comprise a plurality of nodes representing at least 1,000,000 nucleotides stored in a storage medium, and thus cannot be reasonably performed as a mental process and do not recite a mathematical concept. This position is further supported by applicant's arguments that the claims provide an improvement the technology by improving the accuracy of genotyping (see remarks filed 10/09/2026, pages 14-16). For these reasons, the claims are patent eligible. Claim rejections - 35 USC § 112b The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21, 24-26, 28, 31-35, 38-42 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims that depend directly or indirectly from claim(s) 21, 28, 35 are also rejected due to said dependency. Claims 21, 28, 35 recite “aligning a plurality of sequence reads a sequence read to the reference DAG data structure representing the at least 1,000,000 nucleotides, the plurality of sequence reads having been obtained from a genetic sample”. In this case, the phrase “having been obtained from a genetic sample” is a past-tense limitation directed to how or where the sequence reads were obtained at a previous point in time. As a result, it is unclear what limiting effect of the claimed method is intended since limitations directed to the nature of the data, per se, have no limiting effect on the method as claimed. See also MPEP § 2111.04. Clarification is requested via amendment. In order to advance prosecution, the examiner suggests amending the claims to include a step of “obtaining a plurality of sequence reads from a genetic sample”. Claims 21, 28, and 35 recite “creating, in the at least one non-transitory computer-readable storage medium, relationships between the sequence read and strings associated with respective nodes in the reference DAG data structure, the strings including the first string associated with the first node and the second string associated with the first alternate node.” In this case, it is unclear what is meant by “relationships between the sequence read and strings associated with respective nodes”. Stated differently, the term ‘sequence read’ is singular and the terms “relationships” and “strings” are plural. As such, it is unclear in what way a single read have multiple relationships between strings. If the claim recited “relationships between a plurality of sequence reads and strings associated with respective nodes”, for example, this issue would be sufficiently addressed. Claims 21, 28, 35 recite “evaluating a plurality of alignments between the sequence read and the reference DAG data structure by comparing the sequence read to the strings associated with the respective nodes in the reference DAG data structure based on degrees of overlap indicated in the relationships, the degrees of overlap including a degree of overlap between the sequence read and the first string of the plurality of symbols and a degree of overlap between the sequence read and the second string of the plurality of symbols.” Firstly, there are no previous steps that result in determining or indicating ‘degrees of overlap’ in said relationships such that it can be used on said “evaluating”. Accordingly, there is lack of antecedent basis for “degrees of overlap indicated in said relationships”. As a result, the claims also appear to be missing essential subject matter. The missing essential subject matter appears to be calculating or determining ‘degrees of overlap’. Clarification is requested via amendment. Secondly, it is unclear what is meant by “degrees of overlap”. The term “degree” is relative term and specification does not provide any limiting definitions, specific properties, or criteria that would serve to clarify the scope, i.e. the result is subjective and imperceptible. The specification does teach “determining the smallest number of overlapping bases (p) between the sequence read and a portion of the reference sequence construct” and overlap values [see pages 8 and 15]. However, this is not commensurate in scope with what is being claimed and does not clarify the issue. Clarification is requested via amendment, e.g. by removing the relative term. Lastly, it is unclear what limiting effect is intended by the phrase “based on degrees of overlap indicated in the relationships”, i.e. in what way is the ‘degrees of overlap’ information being used to achieve said evaluating. A review of the specification does not provide any computational techniques, equations, or prose equivalent that would serve to clarify the issue. The specification does generally describe algorithms for evaluating quality of an alignment and determining overlap values [pages 15, 16, and Figures 4 and 5]. However, this is not commensurate in scope with what is being claimed and it is improper to import narrowing limitations into the claims. MPEP 2111.01. As a result, it is unclear what computational techniques are included or excluded by the claimed “evaluating” step such that one of ordinary skill in the art would know how to avoid infringement. Clarification is requested via amendment. Suggestions for Improved Clarity and Precision In order to improve the clarity and precision of the claimed invention, Applicant is encouraged to consider the following amendment(s): The examiner suggests amending claims 25, 28, and 35 to include identifiers for all positive process steps, e.g. i) obtaining…, ii) aligning…, etc., and wherein these process steps comprise one or more steps, additionally including sub-identifiers for all of the sub-steps, e.g. ii) aligning…comprising: a), creating…; b) evaluating…; etc. Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b). Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 21, 28, 35 is/are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21, 23, 25, 30, 32-34 of copending application 17/359338 (Notice of Allowance issued on 10/06/2026). Although the conflicting claims are not identical, they are not patentably distinct from each for the following reasons. In the present case, reference claim 21 of the ‘338 application recites all the limitations of those required by instant claims 21, 28, 35 plus additional limitations. Therefore, instant claim(s) 21, 28, 35 are anticipated by the narrower claims (i.e. species anticipates the genus). This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claims 21, 28, 35 is/are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-20 of US Patent 10,832,797. Although the conflicting claims are not identical, they are not patentably distinct from each for the following reasons. In the present case, reference claims 1, 3, 13 of the ‘797 patent recites all the limitations of those required by instant claims 21, 28, 35 plus additional limitations. Therefore, instant claim(s) 21, 28, 35 are anticipated by the narrower claims (i.e. species anticipates the genus). Claims 21, 28, 35 is/are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-19 of US Patent 11,049,587. Although the conflicting claims are not identical, they are not patentably distinct from each for the following reasons. In the present case, reference claims 1 and 3 of the ‘578 patent recites all the limitations of those required by instant claims 21, 28, 35 plus additional limitations. Therefore, instant claim(s) 21, 28, 35 are anticipated by the narrower claims (i.e. species anticipates the genus). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PABLO S WHALEY whose telephone number is (571)272-4425. The examiner can normally be reached between 1pm-9pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anita Coope can be reached at 571-270-3614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PABLO S WHALEY/Primary Examiner, Art Unit 3619
Read full office action

Prosecution Timeline

Show 3 earlier events
Apr 24, 2025
Final Rejection mailed — §112, §DOUBLEPATENT
Sep 24, 2025
Request for Continued Examination
Oct 03, 2025
Response after Non-Final Action
Oct 22, 2025
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Mar 12, 2026
Notice of Allowance
Oct 09, 2026
Request for Continued Examination
Oct 14, 2026
Response after Non-Final Action
Oct 20, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788330
CONFIGURABLE PATIENT MONITORING SYSTEM
10y 0m to grant Granted Nov 10, 2026
Patent 12718954
Unsupervised Machine Learning Methods
2y 0m to grant Granted Aug 25, 2026
Patent 12688905
SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS
2y 12m to grant Granted Jul 21, 2026
Patent 12633374
METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT
4y 11m to grant Granted May 19, 2026
Patent 12620473
A METHOD AND DOSING CONTROLLER FOR ADMINSTERING A CORRECTION DOSE OF INSULIN
2y 11m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
25%
Grant Probability
46%
With Interview (+21.4%)
High
PTA Risk
Based on 544 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month